Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IM19 CAR-T in relapsed or refractory CD19-positive aggressive non-Hodgkin lymphoma
CTR20200754Phase 2Active
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Aug 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of IM19 Chimeric Antigen Receptor T Cell Injection in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), follicular lymphoma, transformed (t-FL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Immunochina Pharmaceuticals. Started Aug 2020; status: active.
02
Drugs
IM19 Chimeric Antigen Receptor T Cell Injection
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)follicular lymphoma, transformed (t-FL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on CTR20200754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200754.